Pharmacoepidemiological analysis of the consumption of antibacterial drugs for the treatment of patients with nosocomial infections associated with previous hospitalization in multidisciplinary hospitals in the Tomsk region

Abstract

BACKGROUND: Healthcare-associated infections (HAIs) are one of the common complications associated with patients’ stay in a medical organization. An urgent practical problem is the choice of antibiotic therapy for the treatment of patients with nosocomial infections because these infections are caused by antibiotic-resistant strains. HAIs associated with previous hospitalization (HAPH) manifest in patients after discharge from the hospital, and their risk of isolating resistant strains often remains unrecognized by specialists. Thus, more studies are required to examine the structure of HAPH pathogens and patterns of consumption of antibacterial drugs for the treatment of HAPH to further determine antibiotic therapy in these patients.

AIMS: To analyze the use of antibiotic therapy for the treatment of HAPH with known etiological agents and the level of antibiotic resistance.

MATERIALS AND METHODS: The study analyzed the results of a multicenter descriptive retrospective study based on the Clinics Siberian State Medical University and the State Clinical Hospital No. B.I. Alperovich (Tomsk). A total of 108 HAPH cases were examined according to the medical records of inpatients (Form 003/y). For pharmacoepidemiological analysis, the anatomical therapeutic chemical/defined daily dose (DDD) methodology was used, and antibiotic intake was assessed using the number of established daily doses. The etiological structure of HSV microorganisms was evaluated using the AMRcloud online platform. Quantitative and qualitative indicators were presented as shares (%) and absolute numbers.

RESULTS: In total, 116 isolates from patients with HAPH were assessed. Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Staphylococcus aureus, and Escherichia coli were the dominant pathogens causing HAPH in the overall distribution of pathogens. For the treatment of these patients, a wide range of drugs was used, including 13 groups of antibiotics. In most cases, the parenteral route of drug administration was used: intravenous route, 56.0%; intramuscular, 28.0%; and oral, 16.0%. The DDD analysis showed that antibiotic intake for the treatment of patients with HAPH was 137.8 NDDD/100 bed-days; surgical infection, 48.2 NDDD/100 bed-days (35.0%); and pneumonia, 89.6 NDDD/100 bed-days (65.0%). Cephalosporins were the most commonly used group of antibiotics for both surgical infection and pneumonia, mainly third-generation cephalosporins.

CONCLUSION: Etiological agents of HAPH are phenotypically similar to nosocomial strains. Among antibacterial drugs, cephalosporins and fluoroquinolones were mainly consumed, and HAPH isolates had unfavorable resistance profiles to these drugs.

Keywords

antibiotic resistance / nosocomial infections / pharmacoepidemiologic analysis / ATS/DDD methodology

References

[1] Safavi A, Molavynejad S, Rashidi M, et al. The effect of an infection control guideline on the incidence of ventilator-associated pneumonia in patients admitted to the intensive care units. BMC Infect Dis. 2023;23(1):198. doi: 10.1186/s12879-023-08151-w

[2] Safavi A., Molavynejad S., Rashidi M., et al. The effect of an infection control guideline on the incidence of ventilator-associated pneumonia in patients admitted to the intensive care units // BMC Infectious Diseases. 2023. Vol. 23, N 1. P. 198. doi: 10.1186/s12879-023-08151-w

[3] Morozov AM, Zhukov SV, Belyak MA, Stamenkovich AB. Assessment of economic losses due to the development of infection in the surgical intervention area. Manager Zdravoohranenia. 2022;1:54–60. (In Russ). doi: 10.21045/1811-0185-2022-1-54-60

[4] Морозов А.М., Жуков С.В., Беляк М.А., Стаменкович А.Б. Оценка экономических потерь вследствие развития инфекции области хирургического вмешательства // Менеджер здравоохранения. 2022. № 1. С. 54–60. doi: 10.21045/1811-0185-2022-1-54-60

[5] Gabrielyan NI, Sharapchenko SО, Kisil ОV, et al. Epidemiology issues in problem of antibiotic resistance of clinical pathogens. Medical alphabet. 2020;(34):6–8. (In Russ). doi: 10.33667/2078-5631-2020-34-6-8

[6] Габриэлян Н.И., Шарапченко С.О., Кисиль О.В., и др. Вопросы эпидемиологии в проблеме антибиотикорезистентности клинических патогенов // Медицинский алфавит. 2020. № 34. С. 6–8. doi: 10.33667/2078-5631-2020-34-6-8

[7] Polushin YuS, Shlyk IV. Can the efficacy of anti-bacterial therapy of nosocomial infections be enhanced? Messenger of Anesthesiology and Resuscitation. 2020;17(1):6–8. (In Russ). doi: 10.21292/2078-5658-2020-17-1-6-8

[8] Полушин Ю.С., Шлык И.В. Можно ли повысить эффективность антибактериальной терапии нозокомиальных инфекций? // Вестник анестезиологии и реаниматологии. 2020. Т. 17, № 1. С. 6–8. doi: 10.21292/2078-5658-2020-17-1-6-8

[9] Herrera S, Torralbo B, Herranz S, et al. Carriage of multidrug-resistant Gram-negative bacilli: duration and risk factors. Eur J Clin Microbiol Infect Dis. 2023;42(5):631–638. doi: 10.1007/s10096-023-04581-1

[10] Herrera S., Torralbo B., Herranz S., et al. Carriage of multidrug-resistant Gram-negative bacilli: duration and risk factors // Eur J Clin Microbiol Infect Dis. 2023. Т. 42, N 5. P. 631–638. doi: 10.1007/s10096-023-04581-1

[11] Weiner-Lastinger LM, Abner S, Edwards JR, et al. Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015–2017. Infect Control Hosp Epidemiol. 2020;41(1):1–18. doi: 10.1017/ice.2019.296

[12] Weiner-Lastinger L.M., Abner S., Edwards J.R., et al. Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015–2017 // Infect Control Hosp Epidemiol. 2020. Т. 41, N 1. С. 1–18. doi: 10.1017/ice.2019.296

[13] Yakovlev SV, Suvorova MP, Beloborodov VB, et al. Multicentre study of the prevalence and clinical value of hospital-acquired infections in emergency hospitals of Russia: ERGINI Study. Antibiotiki i Khimioterapiya. 2016;61(5-6):32–42. (In Russ).

[14] Яковлев С.В., Суворова М.П., Белобородов В.Б., и др. Распространённость и клиническое значение нозокомиальных инфекций в лечебных учреждениях России: исследование ЭРГИНИ // Антибиотики и химиотерапия. 2016. Т. 61, № 5–6. С. 32–42.

[15] Voropaeva NM, Nemchenko UM, Grigorova EV, et al. Structure and antibiotic resistance of the main causative agents of infections associated with the provision of medical care. Epidemiology and Vaccinal Prevention. 2023;22(1):68–73. (In Russ). doi: 10.31631/2073-3046-2023-22-1-68-73

[16] Воропаева Н.М., Немченко У.М., Григорова Е.В., и др. Этиологическая структура инфекций, связанных с оказанием медицинской помощи, и антибиотикорезистетность основных возбудителей инфекций // Эпидемиология и Вакцинопрофилактика. 2023. Т. 22, № 1. С. 68–73. doi: 10.31631/2073-3046-2023-22-1-68-73

[17] Kuzmenkov AYu, Vinogradova AG, Trushin IV, et al. AMRmap — antibiotic resistance surveillance system in Russia. Clinical Microbiology and Antimicrobial Chemotherapy. 2021;23(2):198–204. (In Russ). doi: 10.36488/cmac.2021.2.198-204

[18] Кузьменков А.Ю., Виноградова А.Г., Трушин И.В., и др. AMRmap-система мониторинга антибиотикорезистентности в России // Клиническая микробиология и антимикробная химиотерапия. 2021. Т. 23, № 2. С. 198–204. doi: 10.36488/cmac.2021.2.198-204

[19] Olivares E, Badel-Berchoux S, Provot C, et al. Clinical impact of antibiotics for the treatment of Pseudomonas aeruginosa biofilm infections. Front Microbiol. 2020;10:2894. doi: 10.3389/fmicb.2019.02894

[20] Olivares E., Badel-Berchoux S., Provot C., et al. Clinical impact of antibiotics for the treatment of Pseudomonas aeruginosa biofilm infections // Front Microbiol. 2020. Vol. 10. P. 2894. doi: 10.3389/fmicb.2019.02894

[21] Heidari R, Farajzadeh Sheikh A, Hashemzadeh M, et al. Antibiotic resistance, biofilm production ability and genetic diversity of carbapenem-resistant Pseudomonas aeruginosa strains isolated from nosocomial infections in southwestern Iran. Mol Biol Rep. 2022;49(5):3811–3822. doi: 10.1007/s11033-022-07225-3

[22] Heidari R., Farajzadeh Sheikh A., Hashemzadeh M., et al. Antibiotic resistance, biofilm production ability and genetic diversity of carbapenem-resistant Pseudomonas aeruginosa strains isolated from nosocomial infections in southwestern Iran // Mol Biol Rep. 2022. Vol. 49, N 5. P. 3811–3822. doi: 10.1007/s11033-022-07225-3

[23] Yang X, Guo R, Zhang B, et al. Retrospective analysis of drug resistance characteristics and infection related risk factors of multidrug-resistant organisms (MDROs) isolated from the orthopedics department of a tertiary hospital. Sci Rep. 2023;13(1):2199. doi: 10.1038/s41598-023-28270-3

[24] Yang X., Guo R., Zhang B., et al. Retrospective analysis of drug resistance characteristics and infection related risk factors of multidrug-resistant organisms (MDROs) isolated from the orthopedics department of a tertiary hospital // Sci Rep. 2023. Vol. 13, N 1. P. 2199. doi: 10.1038/s41598-023-28270-3

[25] Kishita M, Matsumura Y, Yamamoto M, et al. Increase in the frequency of community-acquired methicillin-resistant Staphylococcus aureus clones among inpatients of acute care hospitals in the Kyoto and Shiga regions, Japan. J Infect Chemother. 2023;29(5):458–463. doi: 10.1016/j.jiac.2023.01.013

[26] Kishita M., Matsumura Y., Yamamoto M., et al. Increase in the frequency of community-acquired methicillin-resistant Staphylococcus aureus clones among inpatients of acute care hospitals in the Kyoto and Shiga regions, Japan // J Infect Chemother. 2023. Vol. 29, N 5. P. 458–463. doi: 10.1016/j.jiac.2023.01.013

RIGHTS & PERMISSIONS

Eco-Vector